Efficacy of combining intravitreal injections of ranibizumab with micropulse diode laser versus intravitreal injections of ranibizumab alone in diabetic macular edema (ReCaLL): a single center, randomised, controlled, non-inferiority clinical trial

Table 1 Re-treatment and stopping treatment criteria for pro re nata (PRN) regimen used in the study

Criteria for re-treatment	Criteria for stopping treatment
visual improvement	irreversible changes of central macula (i.e. atrophy, ischemia) without the perspective for visual improvement
decrease in CMT ≥10%^a	BCVA < 35 as measured by ETDRS charts^b
	BCVA of 100 on ETDRS charts
	lack of fluid in the area of the fovea

CMT central macular thickness; BCVA best corrected visual acuity; ETDRS Early Treatment Diabetic Retinopathy Study;
^a thickness evaluation under consideration of cysts and vitreoretinal membrane structures
^b with the exception of visual impairment due to other causes such as vitreous hemorrhage

ISSN: 1471-2415